[Form 4] Royalty Pharma plc Insider Trading Activity
Royalty Pharma's Form 4 reports that the reporting person listed as "Lloyd George W." (identified as EVP, Investments & CLO) acquired 3,696 Class A Ordinary Shares on 08/06/2025 through the settlement of Equity Performance Awards, an exempt acquisition pursuant to Rule 16b-3. The filing also records a disposition of 3,000 Class A shares and shows multiple indirect holdings held by several related entities and the reporting person's spouse.
Table II discloses limited partnership interests in RPI US Partners 2019, LP that are exchangeable: each RPI US LP Interest may be exchanged for ten Class B Interests, and each Class B Interest will be exchanged for one Class A Ordinary Share, meaning each LP interest converts into ten Class A shares. The filing lists underlying Class A equivalents of 581,730, 2,917,390, 2,726,720, 1,301,480 and 85,000 related to those interests. The form was signed by an attorney-in-fact on 08/08/2025.
Il Form 4 di Royalty Pharma indica che la persona segnalante, identificata come Lloyd George W. (EVP, Investments & CLO), ha acquisito 3,696 Class A Ordinary Shares il 08/06/2025 tramite il regolamento di Equity Performance Awards, un'acquisizione esente ai sensi della Rule 16b-3. La comunicazione registra inoltre una cessione di 3,000 Class A shares e mostra pi霉 partecipazioni indirette detenute da varie entit脿 correlate e dal coniuge della persona segnalante.
La Tabella II dichiara interessi in societ脿 in accomandita semplice in RPI US Partners 2019, LP scambiabili: ogni RPI US LP Interest pu貌 essere convertito in dieci Class B Interests, e ogni Class B Interest sar脿 scambiato con una Class A Ordinary Share, perci貌 ogni LP interest si trasforma in dieci Class A shares. La dichiarazione riporta equivalenti sottostanti in Class A pari a 581,730, 2,917,390, 2,726,720, 1,301,480 e 85,000 relativi a tali interessi. Il modulo 猫 stato firmato da un attorney-in-fact il 08/08/2025.
El Form 4 de Royalty Pharma informa que la persona informante identificada como Lloyd George W. (EVP, Investments & CLO) adquiri贸 3,696 Class A Ordinary Shares el 08/06/2025 mediante la liquidaci贸n de Equity Performance Awards, una adquisici贸n exenta conforme a la Rule 16b-3. La presentaci贸n tambi茅n registra una disposici贸n de 3,000 Class A shares y muestra varias participaciones indirectas mantenidas por distintas entidades relacionadas y por el c贸nyuge de la persona informante.
La Tabla II revela intereses en sociedad limitada en RPI US Partners 2019, LP que son canjeables: cada RPI US LP Interest puede intercambiarse por diez Class B Interests, y cada Class B Interest ser谩 canjeado por una Class A Ordinary Share, lo que significa que cada LP interest se convierte en diez Class A shares. La presentaci贸n enumera equivalentes subyacentes en Class A de 581,730, 2,917,390, 2,726,720, 1,301,480 y 85,000 relacionados con esos intereses. El formulario fue firmado por un attorney-in-fact el 08/08/2025.
Royalty Pharma鞚� Form 4鞐� 霐半ゴ氅�, 氤搓碃鞚胳溂搿� 旮办灛霅� Lloyd George W. (EVP, Investments & CLO)臧� 08/06/2025鞐� Equity Performance Awards鞚� 鞝曥偘鞚� 韱淀暣 3,696 Class A Ordinary Shares毳� 旆摑頄堨溂氅�, 鞚措姅 Rule 16b-3鞐� 霐半ジ 氅挫牅 旆摑鞛呺媹雼�. 鞁犼碃靹滌棎電� 霕愴暅 3,000 Class A 欤检嫕鞚� 觳橂秳鞚� 旮半霅橃柎 鞛堦碃, 甏�霠� 鞐煬 氩曥澑瓿� 氤搓碃鞚胳潣 氚办毎鞛愱皜 氤挫湢頃� 雼れ垬鞚� 臧勳爲 氤挫湢 歆�攵勲弰 旮办灛霅橃柎 鞛堨姷雼堧嫟.
響� II電� RPI US Partners 2019, LP鞚� 甑愴櫂 臧�電ロ暅 鞙犿暅毂呾瀯靷洂甓�(limited partnership interests)鞚� 瓿奠嫓頃╇媹雼�: 臧� RPI US LP Interest電� 鞐� 臧滌潣 Class B Interests搿� 甑愴櫂霅� 靾� 鞛堦碃, 臧� Class B Interest電� 1臧滌潣 Class A Ordinary Share搿� 甑愴櫂霅橃柎 瓴瓣臣鞝侅溂搿� 臧� LP interest電� 鞐� 臧滌潣 Class A 欤检嫕鞙茧 鞝勴櫂霅╇媹雼�. 鞁犼碃靹滌棎電� 鞚措煬頃� 鞚挫澋瓿� 甏�霠悳 旮办磮 Class A 靸侂嫻旃橂 581,730, 2,917,390, 2,726,720, 1,301,480 氚� 85,000鞚� 旮办灛霅橃柎 鞛堨溂氅�, 鞏戩嫕鞚� 08/08/2025鞐� attorney-in-fact鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�.
Le Form 4 de Royalty Pharma indique que la personne d茅clarante, identifi茅e comme Lloyd George W. (EVP, Investments & CLO), a acquis 3,696 Class A Ordinary Shares le 08/06/2025 par le r猫glement d'Equity Performance Awards, une acquisition exon茅r茅e en vertu de la Rule 16b-3. Le d茅p么t enregistre 茅galement une cession de 3,000 Class A shares et fait 茅tat de plusieurs participations indirectes d茅tenues par diverses entit茅s li茅es et par le conjoint de la personne d茅clarante.
Le Tableau II r茅v猫le des int茅r锚ts en commandite dans RPI US Partners 2019, LP susceptibles d'锚tre 茅chang茅s : chaque RPI US LP Interest peut 锚tre converti en dix Class B Interests, et chaque Class B Interest sera 茅chang茅 contre une Class A Ordinary Share, ce qui signifie que chaque LP interest se transforme en dix Class A shares. Le dossier liste des 茅quivalents sous-jacents en Class A de 581,730, 2,917,390, 2,726,720, 1,301,480 et 85,000 li茅s 脿 ces int茅r锚ts. Le formulaire a 茅t茅 sign茅 par un attorney-in-fact le 08/08/2025.
Das Form 4 von Royalty Pharma meldet, dass die meldepflichtige Person, aufgef眉hrt als Lloyd George W. (EVP, Investments & CLO), am 08/06/2025 durch die Abwicklung von Equity Performance Awards 3,696 Class A Ordinary Shares erworben hat; dies ist ein gem盲脽 Rule 16b-3 befreiter Erwerb. Die Einreichung verzeichnet au脽erdem eine Ver盲u脽erung von 3,000 Class A Shares und zeigt mehrere indirekte Beteiligungen, die von verschiedenen verbundenen Einheiten und dem Ehepartner des Meldepflichtigen gehalten werden.
Tabelle II legt austauschbare Beteiligungen an RPI US Partners 2019, LP offen: Jeder RPI US LP Interest kann in zehn Class B Interests getauscht werden, und jedes Class B Interest wird gegen eine Class A Ordinary Share getauscht, sodass sich jeder LP Interest in zehn Class A Shares umwandelt. Die Einreichung f眉hrt als zugrundeliegende Class A-脛quivalente 581,730, 2,917,390, 2,726,720, 1,301,480 und 85,000 im Zusammenhang mit diesen Interessen auf. Das Formular wurde am 08/08/2025 von einem attorney-in-fact unterschrieben.
- Exempt acquisition recorded: Settlement of Equity Performance Awards resulted in acquisition of 3,696 Class A Ordinary Shares on 08/06/2025 pursuant to Rule 16b-3.
- Detailed disclosure of indirect holdings: The filing lists sizeable indirect positions across related entities and spouse, including specific amounts such as 273,960 (IRA), 495,860 (GWL 2013 NG, LLC), 220,000 (GWL 2014 G, LLC), 52,000 (GWL 2020 G, LLC), 28,000 (GWL 2021 G, LLC), and 4,011.19 (Spouse).
- Reported disposition: A sale/disposition of 3,000 Class A shares is recorded in the filing.
- Exchangeable LP interests create conversion exposure: RPI US LP Interests are exchangeable into Class A shares at a 10:1 ratio, with underlying Class A equivalents disclosed as 581,730, 2,917,390, 2,726,720, 1,301,480 and 85,000, representing potential increases in Class A share equivalents if exchanged.
Insights
TL;DR: Insider award settlement modestly increases direct holdings; sizable exchangeable LP interests create clear, disclosed conversion rights into Class A shares.
The filing documents an exempt acquisition of 3,696 Class A shares on 08/06/2025 via Equity Performance Award settlement and a reported disposal of 3,000 shares. Of particular note are the RPI US Partners 2019, LP interests that are explicitly exchangeable at a 10:1 ratio into Class A shares (each LP interest -> ten Class A shares). The filing lists explicit underlying Class A equivalents totaling multiple millions of shares across related entities, which is important for capital structure considerations. The transaction itself appears routine for an officer compensation settlement and is disclosed under Rule 16 reporting requirements.
TL;DR: Standard insider reporting and conversion mechanics disclosed; the document increases transparency about related-party indirect holdings and conversion rights.
The Form 4 identifies the reporting person as an officer (EVP, Investments & CLO) and details an exempt award settlement of 3,696 Class A shares. The explanatory notes clearly state the mechanics by which RPI US LP Interests may be exchanged for Class A shares (ten Class A shares per LP interest via Class B Interests). The presence of multiple indirect holdings by affiliated LLCs and the spouse is fully disclosed with specific amounts. From a governance perspective, the filing is comprehensive and meets disclosure norms; it documents potential share-conversion pathways that investors should be able to quantify from the provided numbers.
Il Form 4 di Royalty Pharma indica che la persona segnalante, identificata come Lloyd George W. (EVP, Investments & CLO), ha acquisito 3,696 Class A Ordinary Shares il 08/06/2025 tramite il regolamento di Equity Performance Awards, un'acquisizione esente ai sensi della Rule 16b-3. La comunicazione registra inoltre una cessione di 3,000 Class A shares e mostra pi霉 partecipazioni indirette detenute da varie entit脿 correlate e dal coniuge della persona segnalante.
La Tabella II dichiara interessi in societ脿 in accomandita semplice in RPI US Partners 2019, LP scambiabili: ogni RPI US LP Interest pu貌 essere convertito in dieci Class B Interests, e ogni Class B Interest sar脿 scambiato con una Class A Ordinary Share, perci貌 ogni LP interest si trasforma in dieci Class A shares. La dichiarazione riporta equivalenti sottostanti in Class A pari a 581,730, 2,917,390, 2,726,720, 1,301,480 e 85,000 relativi a tali interessi. Il modulo 猫 stato firmato da un attorney-in-fact il 08/08/2025.
El Form 4 de Royalty Pharma informa que la persona informante identificada como Lloyd George W. (EVP, Investments & CLO) adquiri贸 3,696 Class A Ordinary Shares el 08/06/2025 mediante la liquidaci贸n de Equity Performance Awards, una adquisici贸n exenta conforme a la Rule 16b-3. La presentaci贸n tambi茅n registra una disposici贸n de 3,000 Class A shares y muestra varias participaciones indirectas mantenidas por distintas entidades relacionadas y por el c贸nyuge de la persona informante.
La Tabla II revela intereses en sociedad limitada en RPI US Partners 2019, LP que son canjeables: cada RPI US LP Interest puede intercambiarse por diez Class B Interests, y cada Class B Interest ser谩 canjeado por una Class A Ordinary Share, lo que significa que cada LP interest se convierte en diez Class A shares. La presentaci贸n enumera equivalentes subyacentes en Class A de 581,730, 2,917,390, 2,726,720, 1,301,480 y 85,000 relacionados con esos intereses. El formulario fue firmado por un attorney-in-fact el 08/08/2025.
Royalty Pharma鞚� Form 4鞐� 霐半ゴ氅�, 氤搓碃鞚胳溂搿� 旮办灛霅� Lloyd George W. (EVP, Investments & CLO)臧� 08/06/2025鞐� Equity Performance Awards鞚� 鞝曥偘鞚� 韱淀暣 3,696 Class A Ordinary Shares毳� 旆摑頄堨溂氅�, 鞚措姅 Rule 16b-3鞐� 霐半ジ 氅挫牅 旆摑鞛呺媹雼�. 鞁犼碃靹滌棎電� 霕愴暅 3,000 Class A 欤检嫕鞚� 觳橂秳鞚� 旮半霅橃柎 鞛堦碃, 甏�霠� 鞐煬 氩曥澑瓿� 氤搓碃鞚胳潣 氚办毎鞛愱皜 氤挫湢頃� 雼れ垬鞚� 臧勳爲 氤挫湢 歆�攵勲弰 旮办灛霅橃柎 鞛堨姷雼堧嫟.
響� II電� RPI US Partners 2019, LP鞚� 甑愴櫂 臧�電ロ暅 鞙犿暅毂呾瀯靷洂甓�(limited partnership interests)鞚� 瓿奠嫓頃╇媹雼�: 臧� RPI US LP Interest電� 鞐� 臧滌潣 Class B Interests搿� 甑愴櫂霅� 靾� 鞛堦碃, 臧� Class B Interest電� 1臧滌潣 Class A Ordinary Share搿� 甑愴櫂霅橃柎 瓴瓣臣鞝侅溂搿� 臧� LP interest電� 鞐� 臧滌潣 Class A 欤检嫕鞙茧 鞝勴櫂霅╇媹雼�. 鞁犼碃靹滌棎電� 鞚措煬頃� 鞚挫澋瓿� 甏�霠悳 旮办磮 Class A 靸侂嫻旃橂 581,730, 2,917,390, 2,726,720, 1,301,480 氚� 85,000鞚� 旮办灛霅橃柎 鞛堨溂氅�, 鞏戩嫕鞚� 08/08/2025鞐� attorney-in-fact鞐� 鞚橅暣 靹滊獏霅橃棃鞀惦媹雼�.
Le Form 4 de Royalty Pharma indique que la personne d茅clarante, identifi茅e comme Lloyd George W. (EVP, Investments & CLO), a acquis 3,696 Class A Ordinary Shares le 08/06/2025 par le r猫glement d'Equity Performance Awards, une acquisition exon茅r茅e en vertu de la Rule 16b-3. Le d茅p么t enregistre 茅galement une cession de 3,000 Class A shares et fait 茅tat de plusieurs participations indirectes d茅tenues par diverses entit茅s li茅es et par le conjoint de la personne d茅clarante.
Le Tableau II r茅v猫le des int茅r锚ts en commandite dans RPI US Partners 2019, LP susceptibles d'锚tre 茅chang茅s : chaque RPI US LP Interest peut 锚tre converti en dix Class B Interests, et chaque Class B Interest sera 茅chang茅 contre une Class A Ordinary Share, ce qui signifie que chaque LP interest se transforme en dix Class A shares. Le dossier liste des 茅quivalents sous-jacents en Class A de 581,730, 2,917,390, 2,726,720, 1,301,480 et 85,000 li茅s 脿 ces int茅r锚ts. Le formulaire a 茅t茅 sign茅 par un attorney-in-fact le 08/08/2025.
Das Form 4 von Royalty Pharma meldet, dass die meldepflichtige Person, aufgef眉hrt als Lloyd George W. (EVP, Investments & CLO), am 08/06/2025 durch die Abwicklung von Equity Performance Awards 3,696 Class A Ordinary Shares erworben hat; dies ist ein gem盲脽 Rule 16b-3 befreiter Erwerb. Die Einreichung verzeichnet au脽erdem eine Ver盲u脽erung von 3,000 Class A Shares und zeigt mehrere indirekte Beteiligungen, die von verschiedenen verbundenen Einheiten und dem Ehepartner des Meldepflichtigen gehalten werden.
Tabelle II legt austauschbare Beteiligungen an RPI US Partners 2019, LP offen: Jeder RPI US LP Interest kann in zehn Class B Interests getauscht werden, und jedes Class B Interest wird gegen eine Class A Ordinary Share getauscht, sodass sich jeder LP Interest in zehn Class A Shares umwandelt. Die Einreichung f眉hrt als zugrundeliegende Class A-脛quivalente 581,730, 2,917,390, 2,726,720, 1,301,480 und 85,000 im Zusammenhang mit diesen Interessen auf. Das Formular wurde am 08/08/2025 von einem attorney-in-fact unterschrieben.
FAQ
What insider transactions did Royalty Pharma (RPRX) report on this Form 4?
Who is the reporting person on the RPRX Form 4?
Do RPI US Partners 2019, LP interests convert into Royalty Pharma Class A shares?
How many Class A equivalents are disclosed from the RPI US LP interests?
When was the Form 4 signed and filed?
